文献速递免疫规划传染病防控与疫情报告

基于结核分枝杆菌多糖与轮状病毒ΔVP8*蛋白结合的双价结合疫苗候选研究

Development of a bivalent conjugate vaccine candidate against rotaviral diarrhea and tuberculosis using polysaccharide from Mycobacterium tuberculosis conjugated to ΔVP8* protein from rotavirus.
PubMed 文献 · Vaccine · 2021-10-09

本研究将结核分枝杆菌脂阿拉伯甘露聚糖(LAM)与截短的轮状病毒刺突蛋白ΔVP8*化学结合,评估ΔVP8*作为载体和保護性抗原的双重作用。小鼠免疫实验显示,结合物诱导了针对多糖抗原的强特异性免疫应答,与白喉类毒素(DT)结合物相当,并增强了针对ΔVP8*的抗体滴度和功能性抗体。结果表明ΔVP8*可作为糖结合疫苗的载体蛋白,LAM-ΔVP8*结合物是抗轮状病毒和结核病的有效双价疫苗候选。

要点

  • ΔVP8*可作为糖结合疫苗的载体蛋白并激发针对多糖的免疫应答。
  • LAM-ΔVP8*结合物在小鼠中诱导的抗体应答与DT结合物相当。
  • 结合物增强针对ΔVP8*的抗体滴度和功能性抗体,优于未结合ΔVP8*。

核心结论

  • ΔVP8*可作为糖结合疫苗的载体蛋白,LAM-ΔVP8*结合物是抗轮状病毒和结核病的有效双价疫苗候选。

研究设计与样本

  • 小鼠免疫实验,将结核分枝杆菌LAM与ΔVP8*化学结合,评估免疫应答。

主要发现

  • 结合物诱导针对多糖抗原的强特异性免疫应答,与DT结合物相当。
  • 结合物诱导的针对ΔVP8*的抗体滴度和功能性抗体高于未结合ΔVP8*。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Conjugation of carbohydrate antigens with a carrier protein is a clinically proven strategy to overcome the poor immunogenicity of bacterial polysaccharide. In addition to its primary role, which is to help generate a T cell-mediate long-lasting immune response directed against the carbohydrate antigen, the carrier protein in a glycoconjugate vaccine can also play an important role as a protective antigen. Among carrier proteins currently used in licensed conjugate vaccines, non-typeable Haemophilus influenzae protein D has been used as an antigenically active carrier protein. Our previous studies also indicate that some carrier proteins provide B cell epitopes, along with T cell helper epitopes. Herein we investigated the dual role of truncated rotavirus spike protein ΔVP8* as a carrier and a protective antigen. Capsular polysaccharide lipoarabinomannan (LAM), purified from Mycobacterium tuberculosis (M.tb), was chemically conjugated with ΔVP8*. Mouse immunization experiments showed that the resultant conjugates elicited strong and specific immune responses against the polysaccharide antigen, and the responses were comparable to those induced by Diphtheria toxoid (DT)-based conjugates. The conjugate vaccine induced enhanced antibody titers and functional antibodies against ΔVP8* when compared to immunization with the unconjugated ΔVP8*. Thus, these results indicate that ΔVP8* can be a relevant carrier protein for glycoconjugate vaccine and the glycoconjugates consisting of ΔVP8* with LAM are effective bivalent vaccine candidates against rotavirus and tuberculosis.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Park WJ, Yoon YK, Kim Y, et al. Development of a bivalent conjugate vaccine candidate against rotaviral diarrhea and tuberculosis using polysaccharide from Mycobacterium tuberculosis conjugated to ΔVP8* protein from rotavirus. Vaccine. 2021. PMID: 34642087. doi:10.1016/j.vaccine.2021.09.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。